Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study.

Median DFS was 9.30 vs 5.55 months (HR 0.79, 95% CI 0.60-1.05; P=0.107); the primary endpoint was not met. The abstract reports a more pronounced benefit in resected oligometastatic stage IV disease and a trend toward greater DFS benefit at higher baseline MTM/mL. Grade >=3 adverse events occurred in 73.0% vs 3.3%. OS data were immature (24 events).

ASCO Gastrointestinal Cancers Symposium 2025PubMed 42260101